NO20030081L - Anvendelse av stammer fra parapoxvirus mot organfibroser - Google Patents

Anvendelse av stammer fra parapoxvirus mot organfibroser

Info

Publication number
NO20030081L
NO20030081L NO20030081A NO20030081A NO20030081L NO 20030081 L NO20030081 L NO 20030081L NO 20030081 A NO20030081 A NO 20030081A NO 20030081 A NO20030081 A NO 20030081A NO 20030081 L NO20030081 L NO 20030081L
Authority
NO
Norway
Prior art keywords
organ fibrosis
strains against
against organ
parapoxvirus
parapoxvirus strains
Prior art date
Application number
NO20030081A
Other languages
English (en)
Other versions
NO20030081D0 (no
Inventor
Claudia Hirth-Dietrich
Tobias Schlapp
Angela Siegling
Andreas Knorr
Olaf Weber
Gudrun Theiss
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10122233A external-priority patent/DE10122233A1/de
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of NO20030081L publication Critical patent/NO20030081L/no
Publication of NO20030081D0 publication Critical patent/NO20030081D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24211—Parapoxvirus, e.g. Orf virus
    • C12N2710/24232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Den foreliggende oppfinnelse vedrører humananvendelse av inaktiverte parapoxvirus ved profylakse og behandling av sykdommer som er forbundet med forhøyet kollagenavleiring, idet både indre organer som for eksempel leveren, så vel som også huden og dens forbindelsesstrukturer kan være rammet.
NO20030081A 2000-07-11 2003-01-08 Anvendelse av stammer fra parapoxvirus mot organfibroser NO20030081D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10033581 2000-07-11
DE10122233A DE10122233A1 (de) 2000-07-11 2001-05-08 Verwendung von Stämmen des Parapoxvirus ovis gegen Organfibrosen
PCT/EP2001/007978 WO2002004019A2 (de) 2000-07-11 2001-07-11 Verwendung von stämmen des parapoxvirus ovis gegen organfibrosen

Publications (2)

Publication Number Publication Date
NO20030081L true NO20030081L (no) 2003-01-08
NO20030081D0 NO20030081D0 (no) 2003-01-08

Family

ID=26006334

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20030081A NO20030081D0 (no) 2000-07-11 2003-01-08 Anvendelse av stammer fra parapoxvirus mot organfibroser

Country Status (30)

Country Link
US (1) US6632647B2 (no)
EP (1) EP1303302B1 (no)
JP (1) JP5106736B2 (no)
CN (1) CN1452496B (no)
AR (1) AR028800A1 (no)
AU (2) AU2001285827B2 (no)
BG (1) BG107447A (no)
CA (1) CA2415399C (no)
CZ (1) CZ200372A3 (no)
DK (1) DK200300014A (no)
EE (1) EE200300019A (no)
FI (1) FI20030038A (no)
GB (1) GB2383752B (no)
HK (1) HK1054330B (no)
HR (1) HRP20030097A2 (no)
HU (1) HU227668B1 (no)
IL (1) IL153826A0 (no)
LT (1) LT5064B (no)
LU (1) LU90996B1 (no)
LV (1) LV12991B (no)
MA (1) MA25765A1 (no)
MX (1) MXPA03000278A (no)
NO (1) NO20030081D0 (no)
NZ (1) NZ523535A (no)
PL (1) PL360839A1 (no)
RU (1) RU2003104522A (no)
SE (1) SE0300033L (no)
SI (1) SI21171A (no)
SK (1) SK382003A3 (no)
WO (1) WO2002004019A2 (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
US6752995B2 (en) * 2002-04-15 2004-06-22 Board Of Regents, The University Of Texas System Nucleic acid and polypeptide sequences useful as adjuvants
EP1499355A4 (en) 2001-12-07 2005-10-05 Bayer Pharmaceuticals Corp USE OF PARAPOX B2L PROTEIN FOR THE TREATMENT OF CANCER AND THE MODIFICATION OF IMMUNE RESPONSES
EP1574211A1 (en) 2004-03-09 2005-09-14 Inserm Use of antagonists of the CB1 receptor for the manufacture of a composition useful for the treatment of hepatic diseases
WO2012045473A1 (en) * 2010-10-07 2012-04-12 Technische Universität München Viruses for the treatment of fibrosis
KR20180129779A (ko) 2016-02-16 2018-12-05 고꾸리쯔 다이가꾸 호우징 오사까 다이가꾸 섬유화를 치료하기 위한 의약 조성물
TW201919675A (zh) * 2017-09-07 2019-06-01 德商艾庫瑞斯公司 使用羊副痘疹病毒(Parapoxvirus ovis；PPVO)及至少一種額外抗病毒藥之經B型肝炎病毒(HBV)感染之個體之組合療法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2714665A1 (de) * 1977-04-01 1978-10-05 Mayr Anton Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung
US4360510A (en) * 1979-11-30 1982-11-23 Proctor Julian W Method for screening anti-tumor agents of the reticulo-endothelial stimulant class
US4663306A (en) * 1983-09-23 1987-05-05 Ribi Immunochem Research, Inc. Pyridine-soluble extract-refined detoxified endotoxin composition and use
DE3504940C2 (de) 1984-02-17 1997-11-06 Bayer Ag Multipotente Paramunitätsmediatoren, Verfahren zu ihrer Herstellung und diese Mediatoren enthaltende Arzneimittel
DE3816139A1 (de) * 1987-10-17 1989-04-27 Bayer Ag Verfahren zur herstellung von paramunitaetsinducern
DE4405841C1 (de) * 1994-02-23 1995-01-05 Mayr Anton Prof Dr Med Vet Dr Multipotente Paramunitätsinducer auf der Basis von Kombinationen von Pockenviruskomponenten, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE59704194D1 (de) * 1996-04-15 2001-09-06 Anton Mayr Verwendung von multipotenten paramunitätsinducern aus attenuierten, nicht-immunogenen pockenviren oder parapockenviren zur herstellung von arzneimitteln
DE19922407A1 (de) * 1999-05-14 2000-11-16 Bayer Ag Organ-, gewebs- und zellspezifisches Immuntherapeutikum für chronische virale Infektionen, sowie entzündliche, degenerative und proliferative Erkrankungen insbesondere der Leber sowie Krebs auf der Basis von rekombinantem Parapoxvirus
IL139593A (en) * 2000-11-09 2010-12-30 Biogem Optical Ltd Method for the detection of viable microorganisms

Also Published As

Publication number Publication date
HUP0303830A2 (hu) 2004-04-28
MA25765A1 (fr) 2003-04-01
WO2002004019A3 (de) 2002-08-01
HU227668B1 (en) 2011-11-28
EP1303302A2 (de) 2003-04-23
US6632647B2 (en) 2003-10-14
EP1303302B1 (de) 2009-10-14
LV12991B (en) 2003-08-20
WO2002004019A2 (de) 2002-01-17
CZ200372A3 (cs) 2003-05-14
US20020076418A1 (en) 2002-06-20
EE200300019A (et) 2004-10-15
RU2003104522A (ru) 2004-06-27
SI21171A (sl) 2003-10-31
HUP0303830A3 (en) 2004-10-28
GB0302629D0 (en) 2003-03-12
FI20030038A (fi) 2003-03-10
JP2004502741A (ja) 2004-01-29
NO20030081D0 (no) 2003-01-08
NZ523535A (en) 2004-12-24
SE0300033D0 (sv) 2003-01-10
CN1452496B (zh) 2012-10-10
GB2383752A (en) 2003-07-09
PL360839A1 (en) 2004-09-20
HK1054330A1 (en) 2003-11-28
JP5106736B2 (ja) 2012-12-26
CA2415399C (en) 2011-11-08
HK1054330B (zh) 2005-07-15
SE0300033L (sv) 2003-03-10
GB2383752B (en) 2004-11-24
LT2003008A (en) 2003-07-25
MXPA03000278A (es) 2004-04-05
AU2001285827B2 (en) 2006-11-30
BG107447A (bg) 2003-09-30
HRP20030097A2 (en) 2005-02-28
AR028800A1 (es) 2003-05-21
DK200300014A (da) 2003-03-07
AU8582701A (en) 2002-01-21
SK382003A3 (en) 2003-07-01
IL153826A0 (en) 2003-07-31
LT5064B (lt) 2003-11-25
LU90996B1 (en) 2003-01-08
CN1452496A (zh) 2003-10-29
CA2415399A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
CY1105127T1 (el) Συνθεση για την προληψη καρδιαγγειακων νοσων
UA94390C2 (ru) Применение производных индолинонов, предназначенных для лечения или предупреждения идиопатического фиброза легких
SG149027A1 (en) Substituted urea derivatives for treating cardiac diseases
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
NO20065847L (no) Difenylimidazopyrimidiner og -imidazolaminer som inhibitorer av B-sekretase
WO2003104273A3 (en) THERAPEUTIC EPITOPES AND THEIR USES
ATE508735T1 (de) Pulmonale verabreichung von aminoglykosiden
SI1940786T1 (sl) Bifenilni derivati in njihova uporaba pri zdravljenju hepatitisa C
NO952863D0 (no) Fluoxetin-farmasöytiske sammensetninger
EA200702493A1 (ru) Соединения и способы лечения или предотвращения флавивирусных инфекций
NZ623674A (en) Vip fragments and methods of use
ATE462424T1 (de) Therapeutische anwendung von zerstäubtem s- nitrosoglutathion bei zystischer fibrose
CY1109191T1 (el) Μια νεα χρηση της δεφεριπρονης
TN2011000227A1 (en) Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy
NO20056218L (no) Substituerte pyrrolderivater og anvendelse derav som HMF-CoA reduktase-inhibitorer
AR037556A1 (es) Composicion farmaceutica que comprende un abridor del canal de c1c-2
NO20030081L (no) Anvendelse av stammer fra parapoxvirus mot organfibroser
NO20076405L (no) Anvendelse av 24-nor-UDCA
WO2003059258A3 (en) Compositions and methods for treating heart failure
EA200600374A1 (ru) Замещённые пиперидинофенилоксазолидиноны, обладающие противомикробной активностью, с повышенной in vivo эффективностью
WO2003059265A3 (en) Compositions and methods for treating heart failure
UA85232C2 (ru) Оксабиспидиновые соединения и их применение в лечении сердечных аритмий
BRPI0415187A (pt) composição, método para matar bactérias, e, usos de composição e de bacteriófago
MXPA05011428A (es) Metodo de tratamiento de fibrilacion atrial o trepidacion auricular.
WO2007021933A3 (en) Methods and compositions for use in treating vascular diseases and conditions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application